Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q4 2019 Results - Earnings Call Transcript
02:27pm, Thursday, 13'th Feb 2020
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q4 2019 Results - Earnings Call Transcript
How Incyte Beat Wall Street Estimates in Q4
12:00pm, Thursday, 13'th Feb 2020
The biotech posted strong sales growth for all three of its approved drugs.
Incyte's Fourth-Quarter Report Signals Better Times Ahead
11:18am, Thursday, 13'th Feb 2020
Though the pharmaceutical company reported a big clinical trial failure last month, there are other reasons for optimism.
Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales
10:24am, Thursday, 13'th Feb 2020
Incyte (INCY) beats on earnings & sales in the fourth quarter on strong Jakafi growth.
Incyte (INCY) Q4 Earnings and Revenues Beat Estimates
08:35am, Thursday, 13'th Feb 2020
Incyte (INCY) delivered earnings and revenue surprises of 12.07% and 1.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
06:32pm, Wednesday, 12'th Feb 2020
The drug moves closer to an expanded approval for the skin disorder.
Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA
10:45am, Tuesday, 11'th Feb 2020
The Food and Drug Administration will expedite its review of capmatinib.
Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA
09:04am, Tuesday, 11'th Feb 2020
The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.
Stocks to Watch in February
10:10am, Monday, 10'th Feb 2020
These three stocks have major events coming up this month -- and it's not just the release of earnings that investors will be watching.
Here's Why Incyte Stock Tumbled 16.3% in January
04:12pm, Friday, 07'th Feb 2020
A failed study disappointed investors, but the company's pipeline should withstand the blow.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
09:44am, Friday, 07'th Feb 2020
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.
Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
11:11am, Wednesday, 29'th Jan 2020
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
Incyte (INCY) Gains But Lags Market: What You Should Know
05:50pm, Tuesday, 28'th Jan 2020
Incyte (INCY) closed at $76.46 in the latest trading session, marking a +0.51% move from the prior day.
Incyte's Eczema Drug Ruxolitinib Works in a Late-Stage Clinical Trial
02:44pm, Tuesday, 28'th Jan 2020
But the biotech won't release details about how well it works until later.
Could An Eczema Treatment Pull Incyte Stock Out Of Its Downtrend?
10:12am, Tuesday, 28'th Jan 2020
Incyte stock popped in premarket trading Tuesday after the biotech company said its cream eczema treatment, dubbed ruxolitinib cream, succeeded in the first of two pivotal studies.
The post Could An E
